drugset / Trial / NCT06713057

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

NCT06713057

Phase 2 Not yet recruiting 20 enrolled West China Hospital
NaSingle-groupOpen-labelTreatment

Summary

The current study aims to explore the potential advantages of chemotherapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced or metastatic poorly differentiated or anaplastic thyroid cancer who have undergone conventional therapy in the past or unresectable patients .

Timeline

Start
2024-12-01
Primary completion
2025-12-01
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Intravenous
Subject Cisplatin Other / unclassified Intravenous
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Docetaxel Small molecule Intravenous
Subject Doxorubicin Other / unclassified Intravenous
Subject Gemcitabine Small molecule Intravenous
Subject Paclitaxel Small molecule Intravenous
Subject Pemetrexed Small molecule Intravenous
Subject Vindesine Small molecule Intravenous
Subject fluorouracil Small molecule Intravenous